SFRP4 and early-onset autosomal dominant Alzheimer disease: In addition to the effects beyond weight loss of semaglutide on proteins related to CVD (as discussed above), other significantly regulated proteins in this analysis have previously been implicated in other conditions such as Alzheimer’s disease (TNC58, granulin59,60), T2D (sFRP4 (refs. 61,62)) and metabolic-associated steatohepatitis (LFABP63).